Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India

NCT07446010 | Not Yet Recruiting FDA Drug

• 1 other identifier: 23153
• Study Type: observational
• Target: 33
• Locations: 1 country
• Sites: 6

Brief Summary

Hemophilia A is a genetic condition that makes it hard for blood to clot properly. This happens because the body does not have enough of a protein called Factor VIII, which helps stop bleeding. The main goal of treating someone with hemophilia is to stop and prevent bleeding by giving them the missing Factor VIII. This treatment can be given when a person starts bleeding (called on-demand treatment), or it can be given regularly to prevent bleeding (called prophylactic therapy). In India, most people with hemophilia A get treatment only when they have a bleeding episode, and only a few receive regular preventive treatment. Octocog alfa (also known as BAY 81-8973) is a modern, laboratory-made version of Factor VIII. It is made without using any human or animal materials and has special features that help it work better in the body. In India, Octocog alfa is approved for use in adults and children with hemophilia A to:

• Treat and control bleeding episodes when they happen
• Manage bleeding during surgery
• Prevent bleeding by giving regular treatment The safety and effectiveness of Octocog alfa have been shown in several global studies. This new study is required by Indian health authorities to collect information about how safe Octocog alfa is and how well it works in people with hemophilia A who have already received treatment. The study will look at how Octocog alfa is used in real-life medical practice in India, including how doctors prescribe it, how patients use it, and what treatment results they have.

Conditions

Hemophilia A

Outcome Measures

Primary Outcomes (5)

• Duration of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

  12 weeks

• Severity of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

  The severity (or intensity) of an AE will be evaluated by the Investigator in accordance with the CTCAE v 5.0. \- Grade 1 (Milde): Asymptomatic or mild symptoms ; clinical or diagnostic observations only ; intervention not indicated. - Grade 2 (Moderate): Minimal, local or invasive intervention indicated, limiting age-appropriate instrumental activities of daily living. - Grade 3 (Severe): Severe or medically significant but not immediately life threatening; hospitalization or prolongation of existing hospitalization indicated ; disabling; limiting self-care activities of daily living. - Grade 4 (Life threatening Consequences): Urgent intervention indicated. -Grade 5 (Death): Related to Adverse Event

  12 weeks

• Outcome of treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

  The outcome is defined by the following categories. - Recovered or Resolved: The subject has completely recovered or resolved from the Serious Adverse Event. - Recovered or Resolved with sequelae: As a result of AE , the subject suffered persistent and significant disability / incapacity (e.g., blind, deaf and paralysed ). Any AE recovered with sequelae should be rated as an SAE . - Recovering or Resolving: The subject has begin to recover from the condition or injury , but the event has considered ongoing at a reduced intensity. - Not Recovered or Not Resolved: The AE itself is still present and observable. - Fatal: Death due to SAE, mention the cause of death. Unknown: This term should only be used in cases where the subject is lost to follow up .

  12 weeks

• Treatment administered for treatment emergent adverse event (TEAEs) and serious adverse events (TESAEs)

  12 weeks

• Laboratory test results related to adverse events of special interest (AESIs)rse events (TESAEs)

  hypersensitivity, inhibitor development Tests used will be as per the routine clinical practice followed by the investigator at his/her hospital

  12 weeks

Secondary Outcomes (7)

• Total number of infusions per bleed

  12 weeks

• Dose of Octocog alfa (IU/kg) per bleed

  12 weeks

• Location of bleeds

  12 weeks

• Type of bleeds

  12 weeks

• Severity of bleeds

  12 weeks

Study Arms (1)

Group 1

Male adult patients (aged ≥18 years) with severe Hemophilia A in India, who have been previously treated for at least 100 exposure days to FVIII concentrate(s) and are prescribed Octocog alfa for managing bleeding episodes

Drug: Octocog alfa

Interventions

Octocog alfa DRUG

unmodified, full-length recombinant human FVIII (rFVIII)

Also known as: BAY 81-8973, Kovaltry

Group 1

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Male adult patients (aged ≥18 years) with severe Hemophilia A in India, who have been previously treated for at least 100 exposure days to FVIII concentrate(s) and are prescribed Octocog alfa for managing bleeding episodes

You may qualify if:

• Male patients aged 18 years or older with a documented diagnosis of severe Hemophilia A, defined by a baseline Factor VIII (FVIII) activity level of less than 1% (\<0.01 IU/mL) in accordance with the Hemophilia Severity Classification
• Previously treated with FVIII concentrate(s) (plasma derived or recombinant, including Octocog alfa) either on-demand or prophylactically for at least 100 Exposure Days (EDs).
• Patients for whom the decision to initiate on-demand treatment with Octocog alfa for acute bleeding was made as per the investigator's routine treatment practice. This will include patients who are already on on-demand treatment with Octocog alfa as well.
• Written informed consent from the patient or legal representative

You may not qualify if:

• Known contraindication according to the local prescriber information
• Patients who are participating in an investigational program with interventions outside of routine clinical practice.
• Patients with any other diagnosis of bleeding/coagulation disorder other than Hemophilia A.
• Patients who are on ongoing prophylactic treatment with any FVIII concentrate or non-factor treatments like emicizumab.
• Patients exhibiting any of the following laboratory abnormalities at screening:
• Known platelet count \<100,000 mm3
• Known Serum Creatinine \>2 folds upper the normal limit
• Known Hepatic AST or ALT \>5 folds upper the normal limit
• Patients who have received an on-demand infusion with any other FVIII (different to Octocog alfa), FVII or Activated prothrombin complex concentrate product (aPCC/FEIBA) 72 hours before the enrollment.
• History or presence of FVIII inhibitor with a titer ≥ 0.6 with Nijmegen modified Bethesda Assay (NBA), or a clinical history suggestive of an inhibitor necessitating changes to treatment
• Patient concerns or other barriers precluding adequate understanding or cooperation.

Sponsors & Collaborators

• Bayer: lead

Study Sites (6)

Department of Medicine Assam Medical College & Hospital

Dibrugarh, India

Location

Government of Medical College Kozhikode

Kozhikode, India

Location

Sanjay Gandhi Post Graduate Institute & Medical Sciences

Lucknow, India

Location

Christian Medical College & Hospital

Ludhiana, India

Location

All India Institute Of Medical Sciences

New Delhi, India

Location

Sahyadri Super Speciality Hospital

Pune, India

Location

MeSH Terms

Conditions

Hemophilia A

Interventions

F8 protein, human

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Bayer Clinical Trials Contact

CONTACT

(+)1-888-84 22937; clinical-trials-contact@bayer.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2026
• First Posted: March 3, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): September 30, 2027
• Last Updated: June 18, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

IN (6)